Cullinan Therapeutics Inc
(NAS:CGEM)
$
17.15
0.97 (6%)
Market Cap: 988.43 Mil
Enterprise Value: 502.68 Mil
PE Ratio: 0
PB Ratio: 1.74
GF Score: 30/100 - Cullinan Oncology Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Cullinan Oncology Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Cullinan Oncology Inc To Discuss About Licensing Agreement with Harbour Biomed TranscriptFeb 14, 2023
- Cullinan Oncology Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Taiho To Acquire Cullinan Oncology's Subsidiary, Cullinan Pearl - M&A Call TranscriptMay 12, 2022
- Cullinan Oncology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 13, 2022
- Cullinan Oncology Inc To Host CLN-081 Regulatory Update Webinar TranscriptMar 28, 2022
- Cullinan Oncology Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Cullinan Oncology Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Cullinan Oncology Inc To Provide CLN-081 Clinical Update Webinar Call TranscriptDec 16, 2021
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Cullinan Oncology Inc Pearl Clinical Update Call TranscriptJun 04, 2021
Cullinan Oncology Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 26, 2023 / 06:30PM GMT
Release Date Price:
$10.02
(-3.93%)
Brad Canino
Stifel Nicolaus - Stifel Financial Corp - Analyst
Okay. Thanks, everyone, for continuing to join us for the Stifel Targeted Oncology Days. My name's Brad Canino, a senior analyst here. I'm happy to continue the fireside chat sessions with Cullinan Oncology. With me, I've got Nadim Ahmed, the CEO. Thanks so much for joining us today.
Nadim Ahmed
Cullinan Oncology, Inc. - President & CEO
Great to be with you, Brad.
Questions & Answers
Brad Canino
Stifel Nicolaus - Stifel Financial Corp - Analyst
Now Nadim, can you start with an overview of Cullinan? Talk a little bit about your portfolio construction strategy as well; and the maturity of that portfolio now; and its clinical stage pipeline, of course, across the Phase 1 and pivotal-stage assets.
Nadim Ahmed
Cullinan Oncology, Inc. - President & CEO
Sure. Happy to do that, Brad. Let me start out talking a little bit about our strategic approach to drug discovery, which I think is quite
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)